FAQ on TransCode Therapeutics' Appointment of RNAi Pioneer Phillip Zamore to Its Scientific Advisory Board

Who is Dr. Phillip D. Zamore?

Dr. Phillip D. Zamore is a leading figure in RNA interference (RNAi) research, co-founder of Alnylam Pharmaceuticals, and currently the Chair of the RNA Therapeutics Institute at UMass Chan Medical School. His work in RNA biology and gene silencing mechanisms has earned him election to the National Academy of Sciences.

Why is Dr. Zamore’s appointment to TransCode’s Scientific Advisory Board significant?

Dr. Zamore’s appointment is significant because his expertise in RNAi research and gene silencing mechanisms will strategically enhance TransCode Therapeutics’ RNA-targeted cancer therapy programs, potentially accelerating advancements in treating metastatic diseases.

What is TransCode Therapeutics focused on?

TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.

What is TTX-MC138?

TTX-MC138 is TransCode’s lead therapeutic candidate, focused on treating metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis.

Where can I find more information about TransCode Therapeutics?

More information about TransCode Therapeutics (NASDAQ: RNAZ) is available in the company’s newsroom at https://ibn.fm/RNAZ.

What is BioMedWire?

BioMedWire is a specialized communications platform focusing on the latest developments in Biotechnology, Biomedical Sciences, and Life Sciences, part of the Dynamic Brand Portfolio @ IBN, which provides comprehensive corporate communications solutions.

How can I view the full press release about Dr. Zamore’s appointment?

The full press release can be viewed at https://ibn.fm/03LbD.